Skip to main content

Flexion Therapeutics, Inc. (FLXN)

NASDAQ: FLXN · Delayed Price · USD
6.11 -0.12 (-1.93%)
Sep 20, 2021 4:00 PM EDT - Market closed
Market Cap309.80M
Revenue (ttm)102.74M
Net Income (ttm)-95.05M
Shares Out49.97M
EPS (ttm)-1.92
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,359,064
Open6.07
Previous Close6.23
Day's Range5.88 - 6.22
52-Week Range4.30 - 13.66
Beta1.34
AnalystsBuy
Price Target18.00 (+194.6%)
Est. Earnings DateNov 3, 2021

About FLXN

Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the kne...

IndustryBiotechnology
IPO DateFeb 12, 2014
CEOMichael Clayman
Employees257
Stock ExchangeNASDAQ
Ticker SymbolFLXN
Full Company Profile

Financial Performance

In 2020, FLXN's revenue was $85.55 million, an increase of 17.26% compared to the previous year's $72.96 million. Losses were -$113.71 million, -24.08% less than in 2019.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for FLXN stock is "Buy." The 12-month stock price forecast is 18.00, which is an increase of 194.60% from the latest price.

Price Target
$18.00
(194.60% upside)
Analyst Consensus: Buy

News

Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

BURLINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in a vi...

1 week ago - GlobeNewsWire

Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare Conference

BURLINGTON, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an a...

2 weeks ago - GlobeNewsWire

Flexion Therapeutics Announces Inclusion of ZILRETTA® in American Academy of Orthopaedic Surgeons (AAOS) Clinical Pra...

BURLINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the American Academy of Orthopaedic Surgeons (AAOS) included ZILRETTA (triamcinolone acetoni...

2 weeks ago - GlobeNewsWire

Flexion Therapeutics (FLXN) Upgraded to Buy: Here's What You Should Know

Flexion Therapeutics (FLXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 weeks ago - Zacks Investment Research

Why Is Flexion Therapeutics (FLXN) Stock Gaining On Wednesday?

Flexion Therapeutics Inc (NASDAQ: FLXN) expanded the Phase 1b trial of FX301 in patients undergoing bunionectomy.  Related:   Flexion Therapeutics To Start Testing FX301 For Post-Op Pain In Patients Aft...

3 weeks ago - Benzinga

Flexion Therapeutics Announces Expansion of Phase 1b Trial Investigating FX301 for the Management of Post-Operative Pain

BURLINGTON, Mass., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the expansion of the Phase 1b randomized, double-blind, placebo-controlled trial of FX301 in...

3 weeks ago - GlobeNewsWire

7 Penny Stocks with Millionaire-Maker Potential

These penny stocks have multiple growth drivers powering their businesses. That will push their prices to record heights in the future.

Other symbols:CRNTLOTZSHIPSRGATRVG
4 weeks ago - InvestorPlace

Why Flexion Therapeutics (FLXN) Could Be an Impressive Growth Stock

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Flexion Therapeutics (FLXN).

1 month ago - Zacks Investment Research

Down 24.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Flexion Therapeutics (FLXN)

The heavy selling pressure might have exhausted for Flexion Therapeutics (FLXN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ...

1 month ago - Zacks Investment Research

Flexion Therapeutics Announces Publication of Results from Phase 2 Pharmacokinetics (PK) and Safety Study of ZILRETTA...

BURLINGTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the results from the randomized, open-label, Phase 2 pharmacokinetic (PK) trial of ZILRETTA (...

1 month ago - GlobeNewsWire

Flexion Therapeutics (FLXN) Reports Q2 Loss, Tops Revenue Estimates

Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 12.00% and 0.56%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights

BURLINGTON, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended June 30, 2021.

1 month ago - GlobeNewsWire

Flexion Therapeutics to Report Second-Quarter 2021 Financial Results on August 4, 2021

BURLINGTON, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2021 financial results after the close of the U.S. fi...

1 month ago - GlobeNewsWire

Flexion Therapeutics (FLXN) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors

BURLINGTON, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Utpal Koppikar, Chief Financial Officer of Atara Biotherapeutics, to its ...

2 months ago - GlobeNewsWire

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of 20,440 restricted stock units. ...

2 months ago - GlobeNewsWire

4 Biotech and Life Sciences Stocks Trading Under $10 With Gigantic Upside Potential

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other symbols:CKPTEQRSLS
3 months ago - 24/7 Wall Street

Flexion Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference

BURLINGTON, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an an...

3 months ago - GlobeNewsWire

Flexion Therapeutics Announces Appointment of William T. Andrews, M.D.

BURLINGTON, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that William T. Andrews, M.D., F.A.C.P., will join the company as Chief Medical Officer (CMO...

3 months ago - GlobeNewsWire

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of 8,510 restricted stock units. T...

3 months ago - GlobeNewsWire

New Strong Sell Stocks for June 4th

ASLN, BLRX, FLXN, ICMB, and MRNS have been added to the Zacks Rank #5 (Strong Sell) List on June 4, 2021.

Other symbols:ASLNBLRXICMBMRNS
3 months ago - Zacks Investment Research

Flexion Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference

BURLINGTON, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an an...

3 months ago - GlobeNewsWire

Flexion Therapeutics to Present at the RBC Capital Markets 2021 Virtual Global Healthcare Conference

BURLINGTON, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an ana...

4 months ago - GlobeNewsWire

Flexion Therapeutics: Q1 Earnings Insights

Shares of Flexion Therapeutics (NASDAQ:FLXN) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 40.00% year over year to ($0.57), which missed ...

4 months ago - Benzinga

Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates

BURLINGTON, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended March 31, 2021.

4 months ago - GlobeNewsWire